PubRank

K Kieburtz

Author PubWeight™ 49.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2006 6.86
2 The role of radiotracer imaging in Parkinson disease. Neurology 2005 3.02
3 Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 2000 2.49
4 Volunteering for early phase gene transfer research in Parkinson disease. Neurology 2006 2.27
5 Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004 2.18
6 Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology 2002 2.17
7 Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol 2001 1.91
8 Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs. Neurology 2006 1.69
9 Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993 1.61
10 Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology 2003 1.44
11 Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology 2005 1.25
12 Prevalence of dementia in rural China: impact of age, gender and education. Acta Neurol Scand 2006 1.05
13 Functional decline in Huntington's disease. Mov Disord 1995 1.04
14 Unified Huntington's disease rating scale: a follow up. Mov Disord 1998 0.99
15 Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology 1998 0.97
16 The placebo response in Parkinson's disease. Parkinson Study Group. Clin Neuropharmacol 1999 0.96
17 Core Assessment Program for Intracerebral Transplantation in Huntington's Disease (CAPIT-HD). Mov Disord 1996 0.96
18 Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol 2004 0.93
19 Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology 2000 0.92
20 A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology 2002 0.92
21 A shortened version of the motor section of the Unified Huntington's Disease Rating Scale. Mov Disord 1997 0.90
22 Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology 2001 0.88
23 Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: relationship to TH1 and TH2 cytokine profile. Arch Neurol 2000 0.87
24 Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology 1999 0.85
25 Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case-control study. Acta Neurol Scand 2006 0.85
26 Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996 0.83
27 The prevalence of PD in a nutritionally deficient rural population in China. Acta Neurol Scand 2005 0.83
28 Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci 2006 0.82
29 Caudate volume as an outcome measure in clinical trials for Huntington's disease: a pilot study. Brain Res Bull 2003 0.81
30 Chemical-shift imaging of a spontaneous internal carotid artery dissection: case report. AJNR Am J Neuroradiol 1991 0.81
31 Pooled analysis of phase III with entacapone in Parkinson's disease. Acta Neurol Scand 2014 0.80
32 Of mice and men: a model of HIV encephalitis. Neurology 2000 0.79
33 Clinical research in neurology. From observation to experimentation. Neurol Clin 1996 0.78
34 Stable neurological function in subjects treated with 2'3'-dideoxyinosine. J Neurovirol 1997 0.77
35 HIV or zidovudine myopathy? Neurology 1994 0.75
36 Putaminal Iron Deposition<br />in HIV Infection. J NeuroAIDS 1996 0.75
37 Cerebrovascular complications after primary varicella-zoster infection. Lancet 1992 0.75
38 Avoiding conflicts of interest: responsibilities of authors, reviewers, and editors. Neurology 1998 0.75
39 Efficacy of gadolinium in MR brain imaging of HIV-infected patients. AJNR Am J Neuroradiol 1993 0.75
40 Policies on reporting clinical trials and publishing supplements. Neurology 1997 0.75